Screener
Asset Entities ASST Medical Device — D&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Asset Entities in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Asset Entities’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054985
| Line item | Successor / Three Months Ended June 30, 2026 | Predecessor / Three Months Ended June 30, 2025 |
|---|---|---|
| Employee compensation and benefits | 16,314 | 2,005 |
| General and administrative expense | 6,428 | 1,452 |
| Marketing and advertising | 79 | 102 |
| Depreciation and amortization | 86 | 54 |
| Total operating expenses | 24,396 | 5,201 |
| Investment losses: | ||
| Net unrealized loss on digital assets, at fair value | (228,031) | — |
| Net unrealized loss on investments in preferred equity, at fair value | (5,962) | — |
Item 1. Consolidated Financial Statements
FAQ
- What is Asset Entities's medical device — D&A?
- Asset Entities (ASST) reported medical device — D&A of $31K in Q2 2026.
- What does medical device — D&A mean?
- This represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the business segment. It reflects the wear and tear or expiration of assets used to generate segment revenue. This metric is vital for understanding the capital intensity and reinvestment requirements of the business unit.
Ask your AI about Asset Entities's medical device — d&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude